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In Côte d’Ivoire, tuberculosis (TB) is a common cause of death among HIV-infected antire-
troviral therapy (ART) enrollees. Ivorian guidelines recommend screening for TB and initia-
tion of TB treatment before ART initiation. Compliance with these guidelines can help
reduce TB-related mortality during ART and possibly nosocomial TB transmission.
Methods and Findings
In a retrospective cohort study among 3,682 randomly selected adults (15 years old) start-
ing ART during 2004–2007 at 34 randomly selected facilities, documentation of TB screen-
ing completion, prevalence of active TB at ART initiation, and incidence of TB during ART
were evaluated. At ART initiation, median age was 36 years, 67% were female, and median
CD4 count was 135 cells/μL. Among all 3,682 enrollees, 73 (2%) were on TB treatment at
the time of referral to the ART facility. Among the 3,609 not on TB treatment, 1,263 (36%)
were documented to receive some TB screening before ART initiation; 21% were screened
for cough, 21% for weight loss, 18% for fever, 18% for TB contacts, and 12% for night
sweats. Among the 1,263 screened, 111 (11%) were diagnosed with TB and started TB
treatment before ART. No associations between patient characteristics and probability of
being screened were noted. However, documentation of TB screening completion before
ART varied widely by ART facility from 0–100%. TB incidence during ART was 3.0 per 100
person-years but varied widely by ART facility from 0/100 person-year to 13.1/100 person-
years.
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Conclusions
Screening for TB before ART initiation was poorly documented. Facility-level variations in
TB screening documentation suggest facility-level factors, such as investment in training
programs, might determine documentation practices. Targeting under-performing ART facil-
ities with improvement activities is needed. Variations among facilities in TB incidence war-
rant further research. These incidence variations could reflect differences between facilities
in TB screening, diagnostic tests, documentation practices, or TB risk possibly related to
infection control practices or local community TB incidence.
Introduction
Côte d’Ivoire is a country of 22.8 million people, with 460,000 people living with HIV
(PLHIV), an adult HIV prevalence of 3.5%, and about 28,000 HIV-related deaths per year
[1,2]. In response to the HIV pandemic, the Ivorian Ministry of Health (MOH) and partners
have attempted to rapidly scale-up access to antiretroviral therapy (ART), and despite signifi-
cant challenges, including two recent civil wars, had enrolled about 140,710 persons on ART
by 2014, including 107,453 adults, which corresponds to an ART coverage among all adults
with HIV of about 36% [1,2]. Despite significant progress in scaling up ART, the HIV epidemic
continues to fuel the pre-existing tuberculosis (TB) epidemic in Côte d’Ivoire, which in 2014
had an annual case notification rate of 165 per 100,000 people [3]. In sub-Saharan Africa, TB
remains the most common cause of death among HIV-infected persons, including those who
are receiving antiretroviral therapy (ART) [4–6].
In line with World Health Organization (WHO) guidelines, the Ivorian Ministry of Health
(MOH) recommends routine TB symptom screening for all PLHIV at every clinical visit, and
initiation of TB treatment before ART initiation for those diagnosed as having TB. Compliance
with these guidelines can reduce morbidity and mortality from TB during ART [6,7]. There-
fore, evaluating compliance with TB screening guidelines is an important program evaluation
activity and can indicate opportunities for program improvement [8].
In addition, although the Ivorian MOH does not yet recommend isoniazid preventive ther-
apy (IPT), due to concerns that IPT might select for resistant bacilli when given to patients
with undiagnosed active TB, the results from the recent TEMPRANO trial might spur recon-
sideration of IPT guidelines [9]. The TEMPRANO trial reported a 35% reduction in severe
HIV morbidity when eligible HIV-infected patients were prescribed IPT [9]. Since TB screen-
ing is necessary before IPT prescription, an evaluation of baseline compliance with TB screen-
ing procedures is important if the country were to plan IPT scale-up activities.
In addition to evaluating compliance with TB screening guidelines, evaluating the preva-
lence and incidence of TB during ART is important for understanding TB morbidity among
ART enrollees [10]. Previous studies in Côte d’Ivoire evaluating TB burden and predictors
among ART enrollees have been sub-national and have not examined site-level variations in
TB incidence during ART [11,12]. Understanding variations in TB incidence by facility might
reveal geographic variations in community TB transmission or differences between facilities in
nosocomial TB transmission.
Therefore, we analyzed data from the first nationally representative retrospective cohort
study of adult ART enrollees in Côte d’Ivoire [13] to assess clinician compliance with TB symp-
tom screening guidelines, the prevalence and determinants of active TB among new adult ART
enrollees, incidence of TB during ART, and patient- and site-level determinants of incident TB.
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Methods
Ethics Approval
This study was approved by the Institutional Review Board (IRB) of the United States Centers
for Disease Control and Prevention (CDC) (protocol #5512), the Harvard School of Public
Health IRB, and the Ivorian Ethics Review Committee (Comité National d’Éthique des Sciences
de la Vie et de la Santé). Patient informed consent was not required as only routine, anon-
ymized, monitoring data were collected and analyzed.
Eligibility for ART
During 2004–2007, patients diagnosed with World Health Organization (WHO) stage IV HIV
disease, stage III disease with CD4+ T-cell (CD4) counts<350/μL, or stage I or II disease with
CD4 counts<200/μL, were eligible for ART [7]. Prescription of co-trimoxazole (CTX) was
indicated for all ART patients with CD4 counts350/μL.
Patient Monitoring
At ART initiation, monthly for the first 3 months, and quarterly thereafter, standardized
MOH-recommended medical records were completed to monitor disease progression or
improvement. Patients collected medications monthly from clinic pharmacies where the date
of scheduled antiretroviral (ARV) pick-up appointments and actual ARV pick-up dates were
documented.
Clinicians were recommended to document whether TB screening was performed at each
clinic visit and which TB diagnostic tests were performed. Recommended TB screening prac-
tices for adults included assessment for (1) cough, (2) loss of weight, (3) fever, (4) TB contact
history, and (5) night sweats. Recommended TB tests for all adults screening positive for any of
the TB symptoms (i.e., presumptive TB patients) included: (1) two sputum samples sent for
smear microscopy, (2) one sputum sent for TB culture, and (3) chest X-ray for patients who
were smear-negative. If extra-pulmonary TB was suspected, lymph node aspiration, lumbar
puncture and abdominal ultrasound were additional diagnostic tests available at some facilities.
In reality, only two laboratories provided TB culture; very few presumptive TB patients would
therefore have had sputum samples sent for TB culture. Per Ivorian guidelines, if TB symptom
screening was not documented in the medical record, it was considered not done for both
patient management and program monitoring purposes.
Study Design and Population
This was a retrospective cohort study. Patient-level data were abstracted from standardized,
MOH-recommended medical records onto study questionnaires by trained abstractors from
November 2009 through March 2010. Only medical records of adult patients, 15 years old at
ART initiation, who started ART during 2004–2007, were eligible.
Sample Size
Sample size calculations were performed using Epi InfoTM software (CDC, Epi Info 2008, Ver-
sion 3.5.1, Atlanta, GA). Evaluation of TB incidence was a secondary aim of this retrospective
cohort study; the primary study question was to estimate 12-month ART attrition (death or
loss to follow-up). To achieve a 95% confidence interval (CI) of ±3% around the estimate for
12-month attrition, assuming a design effect of 1.5 [8], and a conservative (i.e., higher than
expected) 12-month attrition percentage of 50% [9], a sample size of 2,301 patient records
was needed. Available funding allowed a sample size of 4,000 medical records.
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Sampling
Of 124 ART facilities in the country by December 31, 2007, 78 had provided ART to50
adults. Only 833 (2.3%) of all 36,943 adult patients who had received ART by December 31,
2007, were enrolled at facilities that had supported<50 patients on ART by this time. To main-
tain feasibility, 35 (45%) of the 78 eligible facilities were selected, using a two-stage sampling
strategy. In stage one, the 78 eligible facilities were divided into three strata based on which
type of organization was largely responsible for implementing the ART program at the site
(non-governmental organization, Ministry of Health (MOH), or the Global Fund for AIDS,
TB, and Malaria (GFATM)). Within these three strata, sub-strata were created according to
site size (number of ART patients ever enrolled). Site size sub-strata were: small (50–250),
medium (251–1,000), and large (>1,000). Within each sub-stratum, SAS software version 9.2
(SAS Institute Inc., Cary, NC) was used to select facilities using probably-proportional-to-size
sampling. Of the selected 35 facilities, 34 agreed to participate.
In stage two, simple random sampling was used to select 4,000 medical records from the 34
selected facilities. Clinic-level sample frames of eligible ART patients were derived from paper
or electronic ART patient registers located at the clinic. The total number of medical records
selected in each sub-stratum was proportional to the number of eligible records in the corre-
sponding sub-stratum in the general adult ART population by 2007.
Treatment Outcome Measures
Any patient taking TB treatment for pulmonary or extrapulmonary TB at ART initiation was
considered to have prevalent TB at ART start. After ART initiation, the first occurrence of TB
treatment for pulmonary or extrapulmonary TB was considered incident TB.
Exposure Variables
Variables routinely collected on the MOH-recommended ART records, including age at ART
start, sex, previous TB diagnoses, weight, World Health Organization (WHO) stage, CD4
count, hemoglobin, and (CTX) prescription, were assessed as possible risk factors for prevalent
and incident TB. Site level variables including site size (number of adult ART patients ever
enrolled), presence of stock outs in the last 12 months, and patient to health care worker ratio
were also assessed as possible predictors of incident TB.
Analytic Methods
Data were analyzed using STATA software version 11.0 (StataCorp, 2009, Stata Statistical Soft-
ware, Release 11, College Station, TX). The anonymized dataset is available upon request from
the analysis working group, comprising the corresponding author, MOH representatives, and
representatives from CDC.
After examining patterns and predictors of missing baseline covariate data, missing data,
which are reported for each baseline covariate of interest in Table 1, were assumed to be miss-
ing at random (MAR), and were imputed using multiple imputation with chained equations
[14]. The ice [15] procedure in Stata was used to create 20 imputed datasets. The imputation
model included incident TB as the event indicator, all study variables, and the Nelson-Aalen
estimate of cumulative hazard [16].
Controlling for survey design, associations between baseline covariates and active TB at
ART start (prevalent TB) were assessed using logistic regression. Survey-adjusted logistic
regression was also used to assess associations between baseline covariates and being success-
fully screened for TB. Controlling for survey design, Cox proportional hazards regression
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models were used to estimate adjusted hazard ratios and 95% confidence intervals (CI). The
proportional hazards assumption was assessed using visual methods and the Grambsch and
Therneau test [17]. Estimates were combined across the imputed datasets according to Rubin’s
rules using the mim procedure in STATA [18].
Results
Data for 3,682 adults enrolled in ART during 2004–2007 were abstracted and analyzed. At
ART initiation, median age was 36 (interquartile range: 31-43), 67% of enrollees were female,
5% were HIV-2-infected or dually HIV-1&2 reactive, and the median CD4 count was 137/μL
(IQR 56-234).
Documentation of TB Symptom Screening
Among all 3,682 enrollees, 73 (2%) were on TB treatment at the time of referral to the ART
facility; TB screening and diagnostic practices for these 73 patients were not documented in the
ART medical records. Among the 3,609 not on TB treatment, 1,263 (36%) were documented to
receive some TB screening before ART initiation at the ART facility; 21% were screened for
cough, 21% for weight loss, 18% for fever, 18% for TB contacts, and 12% for night sweats (Fig
1). All five TB screening questions were only administered to 11% of patients. Documentation
of who screened positive for one or more TB symptoms was not a required field in standard
MOH ART charts and therefore could not be abstracted. However, of 1,263 patients screened
for TB, 105 (8%) were documented to provide sputum for smear microscopy, 360 (25%)
received a chest X-ray, 418 (30%) either provided a sputum sample for microscopy or received
a chest X-ray, and 47 (3%) both provided a sputum sample and received a chest X-ray. Among
the 1,263 with documented TB symptom screening, 111 (11%) were ultimately diagnosed with
TB and started TB treatment before ART initiation. Among the 2,346 who had no documenta-
tion of TB screening before ART, zero patients started TB treatment before ART. Of the 111
TB diagnoses, 32 (25%) had provided at least one sputum sample for smear microscopy, 53
(46%) had received an X-ray, 7 (5%) had provided sputum for microscopy and received an X-
ray, and 33 (35%) had no documentation of providing sputum or being X-rayed.
Predictors of being Screened for TB
No associations between patient characteristics and probability of observing TB symptom
screening documentation in the medical record were observed (S1 Table). No significant
changes in the proportion of ART patients documented to have received any form of TB
screening from 2004 to 2007 in Côte d’Ivoire were noted with 44% screened in 2004, 31% in
2005, 33% in 2006, and 38% in 2007. However, significant variation in pre-ART TB screen-
ing documentation between facilities was observed with the percentage of medical records
documenting screening ranging from 0% to 100% (Fig 2); 25 (74%) of 34 facilities docu-
mented at least some pre-ART TB screening, however, only eight (24%) of 34 facilities
documented pre-ART TB symptom screening for more than 80% of their ART enrollees
(Fig 2).
Predictors of Active TB at ART Initiation
A total of 184 (6%) patients (95% CI, 2–9%) were diagnosed with and treated for active TB at
ART initiation (Table 1). Having more advanced WHO disease stage at ART initiation was
associated with active TB at ART enrollment (p<0.001).
TB among Adults Initiating ART in Côte d'Ivoire
PLOS ONE | DOI:10.1371/journal.pone.0157059 June 8, 2016 7 / 16
ART Regimen Prescription Practices
ART regimen choice was affected by diagnosis of TB at ART initiation. Among HIV-1-infected
patients, compared with patients not diagnosed with TB at ART initiation, a higher proportion
of patients with prevalent TB were prescribed efavirenz-containing regimens (64% vs. 34%)
(Table 2). Among HIV-2-infected and dually HIV-1&2-reactive patients, correct prescription
of two nucleoside reverse transcriptase inhibitors (NRTI) and a protease inhibitor (PI) was
more common among TB co-infected patients, compared with patients not diagnosed as hav-
ing TB (61% vs. 46%).
Incident Tuberculosis
The study did not collect data on TB symptom screening post ART initiation due to funding
and feasibility restrictions. However, during ART, 117 patients were documented to be diag-
nosed with and treated for TB. There were 98 cases of pulmonary TB and 19 cases of extra-pul-
monary TB. The overall rate of documented incident TB was 3.0/100 person-years (PY). TB
Fig 1. Percentages of Adults with Documentation of Screening for the Recommended Five Tuberculosis Symptoms before Antiretroviral Therapy
Initiation in Côte d’Ivoire during 2004–2007*. *Error bars represent 95% confidence intervals derived using survey procedures that accounted for study
design.
doi:10.1371/journal.pone.0157059.g001
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incidence was highest in the first 3 months of ART (5.5/100 PY), and declined to 2.0/100 PY,
1.2/100 PY, and 0.7/100 PY during the time periods of 3–6 months, 6–12 months, and>12
months of ART, respectively.
Although none of the measured patient-level and site-level covariates were associated with
incident TB (S2 Table), wide variations in incident TB were observed between ART facilities,
with TB incidence ranging from 0 per 100 person-years to 13.1 per 100 person-years (Fig 3).
Associations between available site-level characteristics and site-level TB incidence were
explored, but none were statistically significant (S2 Table). No statistically significant associa-
tion was observed between site-level pre-ART TB symptom screening documentation compli-
ance and site-level TB incidence rates after ART initiation.
Discussion
This is the first nationally representative study of TB screening documentation, prevalent TB,
and TB incidence during ART in Côte d’Ivoire’s adult ART program and has several important
findings.
Fig 2. Facility-Level Variations in the Percentage of Adults Screened for Tuberculosis before Antiretroviral Therapy Initiation in Côte d’Ivoire
during 2004–2007.
doi:10.1371/journal.pone.0157059.g002
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TB Screening and Diagnostic Practices
Documentation of TB symptom screening before ART was often missing with only 36% of
medical records documenting screening for at least one TB symptom and only 11% of records
documenting screening for all five symptoms recommended by national guidelines. Even
though it is possible that some patients were screened for TB symptoms but screening was not
documented, this still represents incomplete adherence to national TB screening policy, which
requires both TB screening implementation and documentation [19,20]. Low rates of docu-
mented TB screening at ART facilities have been reported from other countries, including
Mozambique, where only 61% of patients were documented to have been screened for TB
before ART and only 5% were documented to have been screened for all five MOH-recom-
mended TB symptoms [8]. TB symptom screening is important because diagnosis of TB and
initiation of TB treatment before ART can reduce TB-related morbidity and mortality during
ART [21], and can contribute to both nosocomial and community reductions in TB transmis-
sion [22]. In addition, exclusion of active TB can allow initiation of isoniazid preventive ther-
apy (IPT), which has been shown in Côte d’Ivoire [9] and other countries [23] to reduce
incidence of active TB and mortality. If Côte d’Ivoire is to adopt WHO recommendations for
universal IPT prescription to HIV-infected persons, significant improvement in TB screening
documentation is desirable so that the MOH can appropriately monitor and evaluate rollout of
the IPT policy [22].
Table 2. First Line Antiretroviral Therapy Regimen Distribution by Tuberculosis Treatment Status and HIV Type at Antiretroviral Therapy Initiation
in Côte d’Ivoire during 2004–2007.
n N % 95% CI No TB at ART Initiation TB at ART Initiation P-value
HIV-1-infected
D4T+3TC+NVP 1,640 3,464 51% (37%–65%) 53% 23% <0.001
AZT+3TC+NVP 87 3,464 3% (1%–8%) 3% 0%
D4T+3TC+EFV 769 3,464 26% (18%–36%) 24% 56%
AZT+3TC+EFV 304 3,464 10% (6%–15%) 10% 12%
Triple NRTI 115 3,464 3% (1%–5%) 3% 1%
2 NRTI's + PI 94 3,464 2% (2%–3%) 2% 1%
Sub-optimal Regardless of HIV Type* 125 3,464 5% (2%–10%) 5% 6%
Other 14 3,464 1% (0%–2%) 0% 1%
Missing 316 3,780 8%
HIV-2 or Dually HIV-1&2-Infected
D4T+3TC+NVP 28 218 9% (3%–21%) 9% 0% 0.912
AZT+3TC+NVP 7 218 3% (1%–10%) 3% 0%
D4T+3TC+EFV 26 218 14% (6%–30%) 15% 0%
AZT+3TC+EFV 11 218 6% (2%–15%) 6% 16%
Triple NRTI 27 218 11% (5%–22%) 11% 23%
2 NRTI's + PI 99 218 46% (37%–56%) 46% 61%
Sub-optimal Regardless of HIV Type* 14 218 10% (4%–22%) 10% 0%
Other 1 218 1% (1%–1%) 1% 0%
Missing 5 223 2%
Abbreviations: D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; AZT, zidovudine; EFV, efavirenz; NRTI, nucleoside reverse transcriptase inhibitor; PI,
protease inhibitor; CI, confidence interval; TB, tuberculosis;; n, numerator for weighted percentage; N, denominator for weighted percentage.
doi:10.1371/journal.pone.0157059.t002
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Notably, there were no patient-level predictors of screening documentation, suggesting that
clinicians were not preferentially documenting TB screening based on clinical perceptions of
the likelihood of having TB. Instead, variations in TB screening documentation were noted at
the facility-level, similar to other studies [8]. Variations in investment in TB-screening training
and monitoring programs at the site-level might therefore explain the variations in TB screen-
ing documentation observed in this study [8]. Site-level improvement activities targeting
under-performing facilities, might be the most efficient way to improve overall TB screening
implementation and documentation.
Per national guidelines, all patients screening positive for one or more TB symptom should
have submitted a sputum sample for smear microscopy. MOH ART charts do not record who
screened positive for one or more TB symptoms and this is something that could be modified
to facilitate future monitoring of TB screening and diagnostic practices. However, our data
show that 25% of patients screened for TB symptoms received a chest X-ray, whereas only 8%
were documented to provide sputum for diagnosis. This suggests possible low compliance with
sputum sample collection from presumptive TB patients or poor documentation of sputum
collection, a finding which has been observed in other countries, including routine settings in
South Africa [24].
Fig 3. Variations in the Incidence Rate of Tuberculosis during Antiretroviral Therapy between Health Facilities in Côte d’Ivoire during 2004–2008.
doi:10.1371/journal.pone.0157059.g003
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Possible reasons for low documented compliance with sputum collection from presumptive
TB patients include: (1) lack of smear microscopy services at many ART clinics, (2) clinician
frustration with long sample turnaround times or lost samples, (3) clinician knowledge that a
negative smear microscopy result for an HIV-positive presumptive TB patient carries low neg-
ative predictive value [25], (4) difficulty collecting sputum samples from presumptive TB
patients who might not be coughing [24], (5) lack of a designated outdoor coughing spot or
patient stigma associated with using the coughing spot [26], or (6) insufficient training in the
national TB diagnostic algorithm. A consequence of low sputum collection rates is that, of the
111 new TB diagnoses prior to ART initiation, only 32 (25%) were documented to have pro-
vided sputum, suggesting that at least 75% of TB diagnoses were not bacteriologically con-
firmed and TB treatment was started based on clinical picture alone, or clinical picture in
conjunction with X-ray findings. Further research into reasons for non-compliance with spu-
tum collection policy is warranted as the new Xpert MTB/RIF assay is rolled out; continued
failure to collect sputum samples from presumptive TB patients would significantly blunt any
impact of the improved TB diagnostic [24,27].
This study observed a 6% TB prevalence overall among all 3,682 ART enrollees, with 111
TB patients diagnosed after TB screening at the ART clinic but before ART initiation, and 73
TB patients diagnosed prior to referral to the ART clinic. This overall prevalence is similar to
other routine program reports from Côte d’Ivoire [11]. However, TB was diagnosed and treat-
ment started for 111 (11%) of the 1,263 patients with some documentation of TB screening
before ART. Since our data show that clinicians were not preferentially screening sicker
patients, it might be reasonable to assume that 11% of the 2,346 patients who were not screened
for TB before ART, might have been diagnosed and treated for TB if they had been screened
for TB. This would mean that about 258 (11% x 2,346) cases of prevalent TB might have been
missed before ART initiation. With a possible total of 442 TB cases at ART initiation (184 of
whom were diagnosed before ART and 258 of whom remained undiagnosed at ART start), this
suggests as many as 58% (258/442) of prevalent TB cases might have been missed before ART
initiation. Given that TB screening and diagnostic procedures are not 100% sensitive, an even
higher proportion of prevalent TB cases might have been missed. Patients with undiagnosed
TB at ART initiation are at risk of Immune Reconstitution Inflammatory Syndrome (IRIS) due
to unmasking of TB symptoms or worsening of existing TB symptoms, since TB symptoms are
dependent on both bacillary burden and immune response [28]. In addition, undiagnosed TB
is thought to be a common cause of death during ART [6,7,29]. Therefore, improvements in
TB screening before ART could significantly reduce morbidity and mortality during ART,
which is an important priority for ART program managers.
Importance of Early ART
Similar to other studies [8,10], markers of advanced disease were predictive of prevalent TB at
ART initiation, and TB incidence declined sharply over time after ART was started. Both these
findings highlight the importance of early ART initiation; earlier diagnosis, linkage to HIV
care, and early ART initiation can reduce TB morbidity for the patient [9], and contribute to
reductions in TB incidence in the community [30].
Antiretroviral Therapy Regimens
Because Rifampicin is a potent inducer of many genes controlling drug metabolism and trans-
port, including the Cytochrome P450 iso-enzymes, and appears to reduce plasma levels of nevi-
rapine more than efavirenz, the WHO recommends using efavirenz in initial ART regimens
for patients concurrently taking TB treatment [31]. In line with these guidelines, efavirenz was
TB among Adults Initiating ART in Côte d'Ivoire
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more commonly prescribed to HIV-1-infected patients with prevalent TB compared with
patients not on TB treatment at ART initiation (68% vs. 34%).
Among HIV-2-infected and dually HIV-1&2-infected patients, 30% of HIV-2-infected or
dually HIV-1&2-reactive patients were incorrectly prescribed non-nucleoside reverse tran-
scriptase inhibitors (NNRTIs), antiretrovirals to which HIV-2 is inherently resistant [32]. Sur-
prisingly, co-infection with TB was associated with correct prescription of two nucleoside
reverse transcriptase inhibitors (NRTIs) and a protease inhibitor (PI), with 61% of TB co-
infected patients versus 46% of patients not taking TB treatment prescribed this regimen. This
may indicate that TB co-infected patients living with HIV-2 or dual HIV-1&2-infection were
managed at facilities with greater expertise in HIV-2 management. Similar to previous reports,
these findings suggest training in regimen prescription practices for HIV-2 or dually infected
patients could improve the quality of HIV-2 care [13].
Predictors of TB Incidence
Lack of an association between patient-level risk factors for TB and incident TB may be due to
insufficient sample size, or measurement error. Nine of 34 facilities reported zero TB incidence
during ART which suggests that either clinicians were failing to screen, diagnose and treat TB
or clinicians were failing to document incident TB cases. Among facilities that did document
some TB incidence, TB incidence still varied greatly by site, ranging from 0.4/100 PY to 13.1/
100 PY. The high incidence rates at some facilities are concerning. TB incidence rates of 13.1/
100 PY correspond to an incidence rate of about 13,100 TB cases/100,000 population which is
79 times higher than the national average of 165/100,000. Associations between site-level char-
acteristics and site-level TB incidence were explored, and although scatter plots suggested a
possible association between lower median site-level CD4 count at ART initiation and higher
TB incidence, this association was not statistically significant. Possible explanations for higher-
than-expected TB incidence rates at some facilities might include lower thresholds for empiric
TB treatment at some facilities, or problems with the diagnostic cascade (e.g., higher than
expected false positive TB diagnoses from smear microscopy). Alternately, these facilities
might truly be “hot-spots” for active TB acquisition and transmission. Sub-optimal adherence
to ART might result in sub-optimal CD4 response, which in turn increases TB acquisition risk
[8,30]. Alternately, poor facility-level infection control (e.g. poor ventilation of waiting areas or
no designated outdoor “cough spot”) could mean that transmission of TB at the facility is
increased among ART enrollees. Another explanation is that community-level TB transmission
rates are higher in the community served by the facility. Further research to explore facility var-
iations in TB incidence rates is warranted to facilitate a programmatic response.
Limitations
This study has several limitations. Firstly, true TB incidence rates may be higher than reported
here, due to missed diagnoses caused by inconsistent screening, insensitive TB diagnostic tests,
poor documentation practices, or rare instances where TB may have been diagnosed but treat-
ment not started. However, true TB incidence might also be lower since some patients might
have been prescribed empiric TB treatment when they did not have active TB disease. Sec-
ondly, insufficient sample size might have resulted in insufficient power to detect true associa-
tions. Thirdly, low observed compliance with TB screening guidelines may be due, in part, to
clinician failure to document their TB screening activities. Fourthly, due to funding and feasi-
bility restrictions, this study did not evaluate documentation of TB symptom screening after
ART initiation. Finally, our follow-up period ended in 2010 and country-wide rates of TB inci-
dence and prevalence may have changed in more recent years.
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Conclusion
In this first nationally representative survey of TB screening practices in ART facilities in Côte
d’Ivoire, documentation of TB screening before ART initiation was missing from most ART
charts. The percentage of ART charts documenting some TB screening before ART varied
from 0–100% suggesting that targeting under-performing facilities with site-improvement
activities may be the most efficient approach to improving TB screening implementation and
documentation, which could reduce TB-related morbidity and mortality, as well as nosocomial
TB transmission. Training and mentoring in ART prescription practices, especially for HIV-2
and dually HIV-1&2-infected patients is needed. Earlier diagnosis, linkage to care, and ART
initiation could reduce TB burden among patients and also contribute to reductions in nosoco-
mial and community TB transmission. Wide variations in TB incidence by ART facility war-
rant further research; these variations might reflect differences in compliance with TB
screening and diagnostic practices, differences in TB case documentation, or true differences in
active TB risk due to differences in nosocomial or community-level TB transmission rates.
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